We expect to commence pilot production in the second quarter of 2021 and are expected to produce vaccine samples for our phase III clinical trial and bridging trials for pGX9501 in the second quarter of 2021 in our manufacturing facilities in Suzhou. We expect to complete stage I of our manufacturing facilities at our Suzhou manufacturing base in the second quarter of 2021, which will enable us to be commercial-ready for the anticipated launch of our COVID-19 vaccine. We have obtained vaccine manufacturing permit.

Our manufacturing facility is equipped with brand-new equipment and instrument. Our production equipment includes fermentation system, disc centrifuge, ultrafiltration system, chromatographic system, formulation system, and auto-packaging and filling machinery. Many of our major manufacturing equipment are manufactured by leading international and domestic brands such as GEMU, Labom and Siemens.

We had a manufacturing team of 40 employees, which is led by Dr. Dan LIU, who has more than 15 years of experience in manufacturing biological products, including vaccine products. Our manufacturing team is further categorized into various departments based on our manufacturing process, including production management, solution production, preparation production, quality assurance, quality control, validation, procurement and logistic, and engineering and equipment department.